Related Experiment Video

Updated: Jun 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Entecavir - options and obstacles of an effective treatment for chronic hepatitis B]

M Cornberg1, M P Manns

  • 1Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule, Hannover, Carl-Neuberg Strasse 1, 30625 Hannover. cornberg.markus@mh-hannover.de

Deutsche Medizinische Wochenschrift (1946)
|December 22, 2009
PubMed

Insights

Entecavir effectively suppresses Hepatitis B virus DNA (HBV-DNA) in most patients, offering a new milestone in treating chronic Hepatitis B. However, prior lamivudine resistance can lead to lower response rates and increased entecavir resistance.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Context:

  • Hepatitis B virus DNA (HBV-DNA) levels are critical indicators for liver cirrhosis and hepatocellular carcinoma progression.
  • Effective suppression of HBV-DNA to undetectable levels is a primary therapeutic goal.
  • Direct antiviral drugs achieve this aim in most patients, but drug resistance remains a significant challenge.

Purpose:

  • To evaluate the efficacy and resistance profile of Entecavir in treating chronic Hepatitis B.
  • To compare Entecavir's effectiveness in treatment-naïve patients versus those with prior lamivudine resistance.

Summary:

  • Entecavir demonstrates high antiviral efficacy, with over 90% of HBe-Ag positive patients achieving suppressed HBV-DNA after five years.
  • Resistance rates to Entecavir are low (approx. 1%) in treatment-naïve patients.
  • Patients with prior lamivudine resistance exhibit reduced treatment responses and higher rates of Entecavir resistance due to fewer required mutations.

Impact:

  • Entecavir represents a significant advancement in managing chronic Hepatitis B.
  • Understanding resistance patterns is crucial for optimizing long-term treatment strategies.
  • Further research into managing resistance in pre-treated patients is warranted.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...